Biotechnology company Ophidion is teaming up with Neuronasal, a clinical-stage company focused on nose-to-brain delivery of therapies for central nervous system disorders, to develop ways to deliver treatments for Parkinson’s disease and other conditions to the brain using noninvasive technology. The companies said…
News
Kenai Therapeutics said the first patient has been dosed in a Phase 1 clinical trial testing the safety and efficacy of RNDP-001, its experimental cell replacement therapy for Parkinson’s disease. The REPLACE trial (NCT07106021) is recruiting up to 12 people with moderate to severe idiopathic (of unknown cause)…
Three research teams investigating five high-potential targets for new Parkinson’s disease therapies received initial funding under a multi-year initiative from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grants are the first to be awarded under MJFF’s Targets to Therapies Initiative, which aims to advance the…
ACI-7104, an experimental vaccine being tested in people with early-stage Parkinson’s disease, has been generally well tolerated and is showing early signals that it may slow disease progression, according to interim Phase 2 data from its developer, AC Immune. “The interim Phase 2 data shows the…
Solengepras, an experimental once-daily pill for Parkinson’s disease, significantly reduces the time patients spend with re-emerging symptoms, known as off episodes. New Phase 2 data suggest the treatment reduces both the frequency and length of these difficult periods when standard medication wears off. The trial (…
Dysfunctional nerve cells in the brain’s motor command center may be driving the rigid brain wave patterns associated with Parkinson’s disease, a new supercomputer simulation reveals. The study suggests that specific neurons, known as PT5B, significantly alter brain wave frequency during movement. These neurons are responsible for…
People with Parkinson’s disease exhibit an interplay between the loss of dopamine-producing neurons and overall nerve cell connections, or synapses, in two key brain regions that is distinct from that seen in individuals without the disease, according to a recent study. Researchers demonstrated that in Parkinson’s,…
The Parkinson’s Foundation has published a new journal article outlining a practical pathway for making hospital care more age friendly for older people living with Parkinson’s disease. The work aims to translate — into everyday practices — the Age-Friendly Hospital Measure set forth by the Centers for Medicare…
Aerobic exercise may help alleviate motor symptoms and reduce anxiety in early Parkinson’s disease, but there’s a chance higher-intensity workouts may do more harm than good, a mouse study suggested. The results show that “a broad range of symptoms should be assessed in clinical studies with different exercise…
An analysis of electronic health records from 11.3 million U.S. veterans suggests obstructive sleep apnea nearly doubles the risk of developing Parkinson’s disease. But early treatment with continuous positive airway pressure (CPAP), the standard therapy for the condition, may cut that risk by about 30%, the study found, “If…
Recent Posts
- Blocking 2 proteins could slow Parkinson’s progression: Study
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s